We would love to hear your thoughts about our site and services, please take our survey here.
Interesting about lfds. My own thoughts are the money in DX will be made from something a bit more quantitative - biosensors. Step us from yes/no sticks - eg. How much (protein x) is in this persons blood - bedside machine that tells you in five minutes.
Needs recognition molecule. ABs have been tried but failed. University of Leeds looking at lots and have published. Could firm backbone of next step up in DX. Just not in next 12 months.
Hang on - if he sold off DX .....
I don't understand how it changed so much from day to day. It seems to swing about more than the other shares I have - they just seem to go down and down. Buying Avacta just on what we know now seems to make sense - not sure why it moves when nothing new is released. It does seem inversely correlated to the index - MrR (bless) has suggested news from other companies impacts avacta. Clever and possibly funny.
These message boards confuse the hell out of me. Its like an alternative universe where everything changes constantly, no one believes anyone is genuine and the main objective is to be as rude as you can safe in the knowledge that you are anonymous.
Thank you for this post though. I have just been paid and trying to decide between here, synairgen and avacta but all have dropped today. I get that's the best time to buy but difficult to see through the emotional non rational stuff. I'll look through the above.
PS - did you work out why cpap is a form of ventilation and patients in ITU are sick.
The oncology platform would seem to be the crown jewels of Avacta but information seems to be limited to the company website. The road shows look like a campaign to get more info out there. I am hoping they do something at medical conferences too and we can have a look at more of clinical data. If trial goes to plan then thus could be in clinic very quickly - we know which patients qualify for Dox and we are set up to administer. We know how to assess its effectiveness in any patient.
I've bought these on the recommendation of a friend - I get the data is incomplete and there are risks. She said they are good value despite this - I know they are in an area we don't fully understand but our guts are becoming key to many functions of health - mental health, immunology etc. I guess I have bought on limited knowkedge but would be interested in the updates you mention - I know of some and hopefully this will see a jump in the share price. This is one of five shares I bought after Xmas.
Is it not just one thing or the other. Good results mean the share price gives up (I think a lot). Not so good results mean it doesn't.
Looking at data to date SNG001 seems to have positive impact on a number of key variables. The trial is there to show it does or it doesn't. If great results then surely this drug gets added to the armory and will be used for years. So say SP will go up 5x - after that I don't care cause I'll have sikd at least half and keep rest as a nest egg.
Wow. Not sure why that reaction. I thought BB were to post news for other users. This was published today. I've watched for couple of weeks and posted but get the impression its a closed club?
What would be something you would like to see posted.
Couple of people have suggested I am ndn in disguise. Cannot prove I'm not but your reaction seems more about your thoughts on him than anything to do with Avacta.
You strike me as clever and funny but right now you have misjudged something and come across as a man shouting about voices in his head. Apologies if my post has made it worst.
I'm hoping Avacta announce something similar and go one better with a combined flu test. Colds are problematic but people with either covid or flu should be isolating - difficult to tell apart on occasion
https://www.thetimes.co.uk/article/28522346-8143-11ec-afe3-4426f55f9ac6?
The alveoli are surrounded by a network of incredibly small blood vessels. If blood goes to an alveoli but no air then that blood leaves the lung unoxygenated. It then mixes with oxygenated blood so that the blood leaving the lung is not fully saturated.
My take is that for interferon to work it must be in high concentrations at the site of action. To get those levels in the lung via oral dosing would also cause side effects.
Delivering via nebulizer enables high concentrations in the lung and lower elsewhere. Ideally a pMDI or a dry powder inhaler (think asthma) would be great but those require formulation that get the right particle size to enable deposition in the part of the lung its needed. Not possible with lots of drugs ( hence cystic fibrosus drugs often nebulized).
Think iv interferon's failed in trials - will have a look after work.
If someone else bought microsaic would that cause deep verge a problem especially if it were a competitor.
Hi Rx :-)
Ventilation perfusion mismatching known to be an issue in long covid and may be a consequence of inflammation during acute stage.
This paper might shed some light and relevant to SNG
https://www.nature.com/articles/s41586-020-03065-y
Just read the Myles tweet. Interesting stuff and he did say that it is risky. I think that is true of all shares. Will he go to the roadshows.
He doesn't know what potency is and some of his science explanations don't make sense but I think he has gone to a lot of effort to explain share stuff. Does anyone know what shares he recommends and how they are doing.
Wow wtf?
I have spoken to his mum and she says I'm definitely not him, whoever he is. If you think my spelling is bad you should see my handwriting.
I'm laughing - thought some news was worth a post but now I'm also caught up in who I am and where did Rxdav think he was typing. Brilliant. Mum (not mum) will be so proud.
Antibodies have poor tumor penetrance and can deplete immune cells. High-affinity PD-1 mokecules demonstrated superior tumor penetration without inducing depletion of peripheral effector T cells. Preclinical work highlighted the comparative, favorable pharmacology of small, nonantibody therapeutics for enhanced cancer immunotherapy and immune diagnostics.
https://pubmed.ncbi.nlm.nih.gov/26604307/